Oncternal Therapeutics, Inc.
USPTO PatentsView assignee record - 16 granted patents across 5 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Oncternal ranks #17,968 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 5 technology areas.
- #17,968
- of 49,997 US assignees by volume
- 29th percentile
- by Innovation Score (29.1/100)
- 12.6
- avg claims per patent
- +67%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R17968 · US Corporation #17,968 · 16 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 16 grants
- MID-PACK #17,968/49,997
- PHOTO-FINISH Oetiker Tool
- CPC-NARROW A61P · 5 areas
- INNOV-THIN 29.1/100
- CLAIMS-RICH 12.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-SURGE +67% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Oetiker Tool Corporation (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Oncternal’s 29.1 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Oncternal
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Oncternal Therapeutics · this assignee 29
Oncternal Therapeutics · this assignee
29 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Oncternal's Innovation Score is 29.1/100 (29th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Oncternal?
Each dot is one of Oncternal’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oncternal’s own 12.6 claims/patent is at or below the 16.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Oncternal's grants concentrate
Oncternal Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 93.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (5 grants) versus a trough of 1 in 2019. By volume, Oncternal sits between Oetiker Tool Corporation and Orison, Inc..
Oncternal's three-year grant acceleration
Oncternal Therapeutics, Inc. shows 4 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Oncternal's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Oetiker Tool
Oetiker Tool Corporation
16 patents
- Oldcastle Infrast…
Oldcastle Infrastructure, Inc.
16 patents
- On-x Life
On-X Life Technologies, Inc.
16 patents
- Onmywhey
OnMyWhey, LLC
16 patents
- Optoma
Optoma Corporation
16 patents
- Or-ment
Or-Ment LLC
16 patents
- Ora Metrix
Ora Metrix, Inc.
16 patents
- Orison
Orison, Inc.
16 patents
- Oncternal Therape… ◀
Oncternal Therapeutics, Inc.
16 patents
What this shows Oncternal holds 16 patents at rank #17,971, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Oncternal
By rank, the assignees closest to #17,971 in granted patent volume.
- Oetiker Tool Corporation #17,967 · 16 patents
- Oldcastle Infrastructure, Inc. #17,968 · 16 patents
- On-X Life Technologies, Inc. #17,969 · 16 patents
- OnMyWhey, LLC #17,970 · 16 patents
- Optoma Corporation #17,972 · 16 patents
- Or-Ment LLC #17,973 · 16 patents
- Ora Metrix, Inc. #17,974 · 16 patents
- Orison, Inc. #17,975 · 16 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Oncternal's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Oncternal's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
29 29th percentile higher than 29% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 12.5% |
| 2018 | 3 | 18.8% |
| 2019 | 1 | 6.3% |
| 2020 | 5 | 31.3% |
| 2021 | 1 | 6.3% |
| 2022 | 2 | 12.5% |
| 2024 | 2 | 12.5% |
Which technologies does Oncternal Therapeutics, Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Oncternal Therapeutics, Inc.'s patent record in context - here's where to go next.
- Oncternal Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 93.8% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #17,968 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Oncternal Therapeutics, Inc. against Oetiker Tool Corporation, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 29.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.